- Published at
- by gurufocus.com
mixed
mixed
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with